Journal article
Treatment of refractory obsessive-compulsive disorder with nutraceuticals (TRON): a 20-week, open label pilot study
Jerome Sarris, Gerard J Byrne, Georgina Oliver, Lachlan Cribb, Scott Blair-West, David Castle, Olivia M Dean, David A Camfield, Vlasios Brakoulias, Chad Bousman, Nathan Dowling, Carolyn Ee, Jenifer Murphy, Ranjit Menon, Michael Berk, Suneel Chamoli, Mark Boschen, Chee H Ng
CNS SPECTRUMS | CAMBRIDGE UNIV PRESS | Published : 2022
Abstract
Background Obsessive-compulsive disorder (OCD) is often challenging to treat and resistant to psychological interventions and prescribed medications. The adjunctive use of nutraceuticals with potential neuromodulatory effects on underpinning pathways such as the glutamatergic and serotonergic systems is one novel approach. Objective To assess the effectiveness and safety of a purpose-formulated combination of nutraceuticals in treating OCD: N-acetyl cysteine, L-theanine, zinc, magnesium, pyridoxal-5′ phosphate, and selenium. Methods A 20-week open label proof-of-concept study was undertaken involving 28 participants with treatment-resistant DSM-5-diagnosed OCD, during 2017 to 2020. The prima..
View full abstractGrants
Awarded by NHMRC Clinical Research Fellowship
Awarded by NHMRC Senior Principal Research Fellowship
Funding Acknowledgements
Thanks are extended to the much-appreciated participants in this study. Jerome Sarris is supported by an NHMRC Clinical Research Fellowship (APP1125000). Michael Berk is supported by a NHMRC Senior Principal Research Fellowship (1156072).